[Vol 26] Medi-Scene: Your Weekly Health News Update


MediScene Magazine Vol 26

1. Recovery rate of COVID-19 in India improves to 62.93%: Health Ministry

On Sunday 12th July, a total of 19,235 people did recover from the coronavirus infection. This has prompted an accumulative total number of recovered cases among COVID-19 patients rising to 5,34,620. The Union Health Ministry said that timely action and prognosis has led to a stable increase in total number of recovered cases. “The recovery rate has improved to 62.93% as more people are recovering due to all-round efforts, the recovered cases exceed active cases by 2,42,362.” India, meanwhile, added a record 28,637 cases of coronavirus infection on Sunday, pushing the country’s COVID-19 tally to 8,49,553. The death toll climbed to 22,674 with 551 people succumbing to the disease in a day, according to the ministry’s data updated at 8 am. According to ICMR, a cumulative total of 1,15,87,153 samples have been tested till July 11, with 2,80,151 samples tested on Saturday.

2. Ashwagandha and Yashtimadhu to be tested by IMS BHU for COVID therapy

Institute of Medical Sciences, Banaras Hindu University, is going to start study of utilizing Ashwagandha (Withania somnifera) as a test drug for prophylactic use among frontline health workers and Yashtimadhu (Glycyrrhiza glabra) for supplement therapy with the conventional treatment of conventional medicine like allopathy on Covid-19 patients with mild and moderate symptoms. Head of the department of Rasa Shastra, of ayurveda faculty IMS-BHU and centre coordinator for the project Prof. Anand Chaudhary said, “As a part of the project of ministry of AYUSH, Indian Council of Medical Research and Council of Scientific and Industrial Research launched by Union health and family welfare minister Dr Harshvardhan and Dr Rajesh Kotecha, secretary of ministry of AYUSH on May 9, the university was given assigned the task of conducting studies on Ashwagandha and Yashtimadhu. Ashwagandha will be tested for study in prophylactic use among frontline health workers of SSL Hospital of BHU and other healthcare workers, while Yashtimadhu will be tested as drug for adjunct therapy with the standard treatment of conventional medicine on Covid-19 patients under treatment in BHU with mild and moderate symptoms.” The purpose of the projects are to investigate the efficacy of ayurvedic mediation in Covid-19 patients on standards of conventional biomedical research.

3. New studies find proof that fruit, vegetables & whole grains may stop diabetes

Two findings published this week in BMJ give a nod for eating more fruits, vegetables, and whole grain foods to reduce the risk of developing diabetes. The authors led by Yang Hu, a doctoral student at Harvard T.H. Chan School of Public Health, Boston, Massachusetts said, “These findings provide further support for the current recommendations of increasing whole grain consumption as part of a healthy diet for the prevention of type 2 diabetes.” Correspondingly, in a sizable European case-cohort study, people with higher values for plasma vitamin C and carotenoids (fruit and vegetable intake) had a lower prevalence of type 2 diabetes. Ju-Sheng Zheng, PhD, University of Cambridge, UK, and colleagues said, “This study suggests that even a modest increase in fruit and vegetable intake could help to prevent type 2 diabetes regardless of whether the increase is among people with initially low or high intake.” Hu and colleagues examined pooled data from 158,259 US women who participated in the Nurses’ Health Study (1984-2014) and 36,525 US men who took part in the Health Professionals Follow-Up Study (1986-2016), who were free of diabetes, cardiovascular disease, and cancer. Partakers’ baseline utilization of seven types of whole grain foods, whole grain breakfast cereal, oatmeal, dark bread, brown rice, added bran, wheat germ, and popcorn was established on self-replies to food frequency questionnaires. During an average 24-year follow-up, 18,629 participants developed type 2 diabetes. After adjusting for body mass index, lifestyle, and dietary risk factors, participants in the highest quintile of total whole grain consumption had a 29% lower risk of incident type 2 diabetes. Zheng and colleagues investigated the relationship in 9754 adults who developed new-onset type 2 diabetes and a juxtaposition group of 13,662 adults who remained diabetes-free during an average 9.7-year follow-up, from 340,234 participants in the European Prospective Investigation Into Cancer and Nutrition (EPIC)-InterAct study.The researchers used high-performance liquid chromatography-ultraviolet methods to determine participants’ plasma levels of vitamin C and six carotenoids (α-carotene, β-carotene, lycopene, lutein, zeaxanthin, β-cryptoxanthin), which they used to calculate a composite biomarker score. “These findings provide strong evidence from objectively measured biomarkers for the recommendation that fruit and vegetable intake should be increased to prevent type 2 diabetes,” according to the researchers.

4. 5 things to know about Heart Failure Prevention after Myocardial Infarction

Heart failure (HF), a recurrent complication of myocardial infarction (MI), occurs in 14%-36% of hospitalized patients. Patients with HF can present with a wide spectrum of clinical severity, ranging from asymptomatic left ventricular (LV) dysfunction to cardiogenic shock. Here are five things to know about the prevention and management of HF in patients after MI.

  • Early revascularization in patients with ST-elevation MI (STEMI) and cardiogenic shock is key to improving patient outcomes.
  • The timely introduction and gradual uptitration of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) are fundamental to reducing post-MI morbidity and mortality.
  • While beta-blockers are an integral part of post-MI treatment, early introduction of these drugs can be harmful to patients with post-MI HF.
  • Early initiation of an aldosterone antagonist for patients with EF ≤ 40% and HF or diabetes reduces the risk for mortality and sudden cardiac death.
  • New pharmacologic and nonpharmacologic therapies to prevent HF in patients post-MI are on the horizon, pending additional trial data.

5. Long-studied protein could be a measure of traumatic brain injury

Traumatic brain injury (TBI) or brain trauma occurs from blows to the head, that often leads to life-changing disordering of the brain and a drop of long-term health conditions. TBI is one of the leading causes of disability and death worldwide. It may arise due to an open-skull injury, like a gunshot wound, a fall, or an automobile accident. Scientists at the Walter Reed Army Institute for Research (WRAIR) have lately exhibited that cathepsin B, a well-known protein that is important to brain development and function, can be used as a biomarker, or measure of severity, for traumatic brain injury. Biomarkers are a great source for scientists to dramatically better both the prognosis and categorization of seriousness of TBI. Moreover, they have the potential to prove treatment strategies by designating whether drugs have reached their targets and achieved therapeutic benefits. In Journal of Neurotrauma, the researchers showed that levels of cathepsin B had increased in areas of the injured brain pertinent to controlling the senses, language, memory and other critical executive functions. Dr. Angela Boutte, lead author and section chief of molecular biology and proteomics within the Brain Trauma Neuroprotection Branch at WRAIR said, “Biomarker tests that accurately reflect the extent and severity of injury can dramatically improve the standard of care, minimizing the need for resource-intensive diagnostics like CT or MRI scans in favor of more portable tests. This would allow for early, accurate detection of TBI, whether at the side of the road after an accident or, most importantly, on the battlefield to help guide medical decisions.”

6. Coronavirus Update: Total number of cases cross 9L with more than 28.6k new cases on Monday

On Monday, 28,648 fresh COVIS-19 cases surfaced across the country, taking the total number to 9,07,041, as per data gathered from state governments. With 538 more deaths, the total toll rose to 23,695. While more than 6 lakh patients have so far recovered from the infections, there are 3.12 lakh active cases. At least six states reported their highest single-day efflux in cases, with Andhra Pradesh detecting 1,935 infections, Uttar Pradesh 1,664, Gujarat 902, Madhya Pradesh 575, Punjab 357 and Chhattisgarh 184. Maharashtra recorded 6,497 fresh coronavirus cases, its lowest increase in the last six days. With this, the overall Covid-19 cases in the state stood at 2,60,924 on Monday. Karnataka reported 2,738 fresh cases of Covid-19, the second-highest single-day increase, including 1,315 from Bengaluru. Delhi continued to report a dip in cases, with 1,246 on Monday, while the day’s death toll rose slightly by 40.

Reference link:

  1. https://health.economictimes.indiatimes.com/news/industry/indias-covid-19-recovery-rate-improves-to-62-93-per-cent-health-ministry/76925129
  2. https://health.economictimes.indiatimes.com/news/industry/varanasi-ims-bhu-to-test-ashwagandha-yashtimadhu-use-in-covid-therapy/76941184
  3. https://www.medscape.com/viewarticle/933643
  4. https://www.medscape.com/viewarticle/931015
  5. https://health.economictimes.indiatimes.com/news/industry/long-studied-protein-could-be-a-measure-of-traumatic-brain-injury/76959155
  6. https://health.economictimes.indiatimes.com/news/industry/indias-covid-count-crosses-9-lakh-28-6k-cases-538-deaths-on-mon/76950292


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.